Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.

Share this video  

EHA 2017 | An update on kinase inhibitors from EHA 2017

Barbara Eichhorst • 23 Jun 2017
EHA 2017
Chronic Lymphocytic Leukemia Ibrutinib Idelalisib Rituximab Venetoclax

Barbara Eichhorst, MD from University Clinic of Cologne,
Germany, gives us an update on kinase inhibitors both in development and in the clinic. She discusses ibrutinib long-term follow-up data, idelalisib combined with rituximab and venetoxlax.

More from Barbara Eichhorst

Optimizing frontline therapy in CLL: triplet regimens and testing for MRD 1:49
Optimizing frontline therapy in CLL: triplet regimens and testing for MRD
Barbara Eichhorst • 14 Sep 2025
Practical considerations for physicians managing patients with CLL in the frontline setting 0:59
Practical considerations for physicians managing patients with CLL in the frontline setting
Barbara Eichhorst • 14 Sep 2025
A session on the management of treatment lines throughout the course of CLL 1:33
A session on the management of treatment lines throughout the course of CLL
Barbara Eichhorst • 14 Sep 2025
Epcoritamab monotherapy in first-line Richter’s transformation: 2-year follow-up of EPCORE CLL-1 1:37
Epcoritamab monotherapy in first-line Richter’s transformation: 2-year follow-up of EPCORE CLL-1
Barbara Eichhorst • 14 Sep 2025

Related Videos

Safety & efficacy of the BTK degrader bexobrutideg in R/R CLL: results from an ongoing Phase I study 3:24
Safety & efficacy of the BTK degrader bexobrutideg in R/R CLL: results from an ongoing Phase I study
Nirav Niranjan Shah • 24 Sep 2025
Pirtobrutinib in R/R CLL: ongoing trials and evaluating this agent in earlier lines 1:56
Pirtobrutinib in R/R CLL: ongoing trials and evaluating this agent in earlier lines
Nirav Niranjan Shah • 24 Sep 2025
BTK degraders in CLL: how may these agents shape the field? 1:30
BTK degraders in CLL: how may these agents shape the field?
Nirav Niranjan Shah • 24 Sep 2025
The importance of understanding the mechanisms underlying Richter’s transformation 1:15
The importance of understanding the mechanisms underlying Richter’s transformation
Gianluca Gaidano • 5 Sep 2025
The content of VJHemOnc is intended for healthcare professionals